Published on 01/12/2025

3rd-Party Platforms for COI/COC: Ensuring Due Diligence in Biologics and ATMP Validation

Introduction to Chain-of-Identity and Chain-of-Custody in Biologics

As the demand for biologics and advanced therapy medicinal products (ATMPs) rises, the need for rigorous validation processes within the pharmaceutical landscape becomes increasingly critical. Chain-of-Identity (COI) and Chain-of-Custody (COC) are essential frameworks that safeguard the integrity and traceability of biological materials during their lifecycle. This article provides a comprehensive, step-by-step tutorial for pharmaceutical professionals on ensuring due diligence when utilizing third-party platforms for COI/COC. Special emphasis will be placed on key concepts such as cold transport adherence, viral clearance validation, and compliance with relevant regulatory expectations, specifically from the US FDA, EMA, and MHRA.

Step 1: Understanding the Importance of COI/COC in Validation Processes

The integrity of biologics is paramount; ensuring that products retain their efficacy and safety is a regulatory requirement. This begins with thoroughly understanding COI and COC principles:

• Chain-of-Identity (COI): This involves tracking the identity of biological materials from the point of collection through to the end user. Each transition must be documented to assure traceability.
• Chain-of-Custody (COC): COC refers to the documentation and control of the biological product as it moves through different handling stages, including transport, storage, and processing.

Regulatory frameworks such as FDA guidelines and ICH Q5A(R2) underscore these concepts by requiring robust tracking systems to confirm both the identity and handling of biologics.

Step 2: Assessing Cold Chain Logistics for Biologicals

Maintaining appropriate temperature controls is crucial in the distribution of biologics, particularly during cold chain logistics. The following steps can help ensure due diligence in this area:

• Temperature Mapping: Conduct a temperature study that maps the thermal behavior of the transportation containers and storage facilities. This data will ensure that temperature limits are adhered to during transport.
• Data Loggers: Implement data loggers that provide real-time temperature information throughout the transport process. This feature is essential for immediate corrective action in case of temperature excursions.
• Supplier Qualification: Qualify all third-party logistics providers for cold chain capabilities, verifying their compliance with cGMP and cold chain management standards.
• Documentation Review: Regularly review the delivery records and temperature monitoring reports to maintain compliance and to support audits.

These steps should culminate in a comprehensive cold chain management strategy that aligns with both regulatory standards and best practices, thus ensuring the efficacy of the biological products.

Step 3: Conducting Viral Clearance Validation

Viral clearance validation is a vital process for any biological product to ensure safety from viral contamination. The following thorough approach follows regulatory guidelines and builds confidence in your validation efforts:

• Risk Assessment: Evaluate the potential viral contamination risks associated with the biological material being processed. This involves identifying potential sources of viral contamination and evaluating their likelihood.
• Spiking Studies: Perform spiking studies by introducing known quantities of viral agents in a controlled manner to validate the effectiveness of the clearance processes. Document the results rigorously.
• Utilizing Closed Systems: Adopt closed systems wherever possible during the manufacturing process to minimize exposure and the risk of contamination.
• Regulatory Compliance: Ensure compliance with regulatory documentation requirements relating to viral clearance validation, referencing guidelines such as ICH Q5A(R2) and EMA’s guidance.

Viral clearance studies must be validated with appropriate methodologies and documented evidence of results in order to satisfy both regulatory scrutiny and internal quality assurance checks.

Step 4: Implementing Aseptic Controls, Especially in Annex 1 Compliance

The need for stringent aseptic controls has been highlighted by the latest updates to Annex 1 of the EU GMP guidelines. These updates aim to ensure that products intended for human use are manufactured in a manner that minimizes contamination risks. Here’s how to approach this aspect comprehensively:

• Facility Design: Evaluate the design of the manufacturing space to ensure it supports aseptic processing. This can include considerations for air flow, clean room classification, and personnel flow.
• Environmental Monitoring: Establish a robust environmental monitoring program to track microbial contamination in the cleanroom and surrounding areas. Regularly analyze the data to ensure compliance with predefined limits.
• Training Personnel: Regularly train personnel on aseptic techniques, procedures, and the importance of maintaining control measures in product handling.

By adhering to these updated requirements, organizations can enhance their control measures, thus reducing the likelihood of contamination in biologics and ATMPs.

Step 5: Establishing Potency and Identity Critical Quality Attributes (CQAs)

Critical Quality Attributes (CQAs) such as potency and identity must be defined and monitored as part of a comprehensive validation process. The following strategies help ensure CQAs are thoroughly established:

• Define CQAs: Work collaboratively with analytical teams to define CQAs that align with product specifications and regulatory expectations. Potency identity is particularly important for biologicals.
• Regular Testing: Implement routine assays to monitor CQAs throughout the product lifecycle. This includes pre-and post-manufacturing assessments to confirm the product remains within acceptable limits.
• Lifecycle Management: Develop a lifecycle management plan to address changes in production processes, which may affect CQAs.

Proper management of CQAs not only helps in meeting regulatory compliance but also supports product consistency and reliability in the market.

Step 6: Tailoring PPQ and CPV for ATMPs

Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) are critical components in validating biologics and ATMPs. Effective tailoring of these processes requires a comprehensive understanding of both regulatory expectations (such as from the ICH Q5A(R2)) and operational capabilities:

• Tailoring PPQ to Specific Biologics: Each biologic or ATMP requires unique considerations in its PPQ plan, informed by specific characteristics and processing steps to ensure all critical attributes are adequately evaluated.
• Continuous Monitoring: Employ continuous monitoring strategies that allow for real-time data collection against defined metrics. This allows for proactive adjustments in the manufacturing process.
• Regulatory Submission and Compliance: Prepare comprehensive documentation outlining the PPQ and CPV processes in submissions to regulatory bodies, ensuring clear communication of all tailoring efforts.

The emphasis on tailored PPQ and CPV strategies strengthens the validation framework and aligns operational strategies with regulatory compliance.

Conclusion: Ensuring Comprehensive Due Diligence in Third-Party Platforms for COI/COC

In conclusion, the validation of biologics and ATMPs is a multifaceted process that requires close attention to regulatory expectations, particularly in relation to Chain-of-Identity and Chain-of-Custody. By following the steps outlined in this tutorial, professionals in the pharmaceutical and biological industries can uphold a high level of due diligence when employing third-party platforms. Adopting robust procedures around cold chain logistics, viral clearance validation, aseptic controls, and monitoring CQAs collectively contributes to a validated and compliant production process.

The stakes are high in biologics; diligent adherence to these steps ensures not only regulatory compliance but, more importantly, patient safety and product integrity down the line.